Ablation Devices Market: Energy Platform Transition, Consumable Economics, and Electrophysiology Laboratory Access

The 2020 to 2025 period split cleanly in half. Elective electrophysiology work collapsed through the pandemic and rebuilt slowly, so growth ran below 6% until 2023. Then pulsed field approvals landed in Europe and the United States and the market accelerated hard, closing the period at a historical rate near 8.2%. Deferred backlogs and an energy transition arrived together.
Base case growth of 9.4% rests on three mechanisms. Atrial fibrillation ablation volumes keep expanding as guidelines move ablation earlier in the treatment pathway rather than after drug failure. Pulsed field raises average selling price per case above the radiofrequency catheters it replaces, so revenue grows faster than procedure count. And single-shot workflow shortens case time enough that a laboratory adds cases without adding rooms, converting capital that already exists into higher consumable throughput every year.
The bull case at 10.7% turns on first-line ablation reimbursement widening beyond the United States and Germany into Japan and the larger European systems. The bear case at 8.2% is a specific one: a haemolysis or coronary spasm safety signal serious enough to trigger label restrictions on pulsed field catheters would stall the conversion and hand two or three years back to thermal energy.